Welcome to our dedicated page for Pro-Dex Colo SEC filings (Ticker: PDEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the story behind Pro-Dex鈥檚 precision surgical drivers and motion-control boards? Most investors start by scanning a single Form 8-K, then realise the real details hide across hundreds of pages of 10-K, 10-Q and proxy statements. This page brings every Pro-Dex SEC filing into one place and, more importantly, explains what each document means for revenue tied to a handful of medical-device OEMs, FDA compliance costs, and new driver technology in development.
Use Stock Titan鈥檚 AI summaries to turn the dense language of a Pro-Dex annual report 10-K simplified into clear bullet points, or let our engine flag sudden shifts in backlog within the latest Pro-Dex quarterly earnings report 10-Q filing. Need immediate alerts? We stream Pro-Dex Form 4 insider transactions real-time so you can track director purchases the moment they hit EDGAR. Curious about pay packages? The Pro-Dex proxy statement executive compensation section is distilled so you can compare cash bonuses to patent milestones in seconds.
Common tasks become effortless: monitor Pro-Dex insider trading Form 4 transactions before material announcements, dissect segment margins with our Pro-Dex earnings report filing analysis, and see every Pro-Dex 8-K material events explained without opening a single PDF. Whether you鈥檙e underwriting credit, valuing the stock, or simply understanding Pro-Dex SEC documents with AI, this hub delivers all filings, real-time updates, and plain-English insights鈥攕o you spend time on decisions, not document mining.
Pro-Dex, Inc. filed its Form 10-K for fiscal 2025 describing operations in medical and scientific devices, including segment sales, balance sheet highlights, financing activity, and governance disclosures. Repairs revenue rose to $18,586 (up from $16,505), CMF sales totaled $9,943 (down ~4%), and thoracic sales increased by $1.3 million to $4.3 million. Operating income improved to $10,689 from $7,173. Investments carried net unrealized gains of $3.3 million at June 30, 2025 versus $1.8 million a year earlier. The company purchased a property for $6.5 million financed with a $5.2 million Property Loan. The revolving credit line was increased to $11.0 million and term loans carry maturities through 2029鈥�2030 with a $3.1 million balloon due at maturity. Share repurchases totaled 130,148 shares at $3.5 million in fiscal 2025. The filing discloses customer concentration (major customer represented ~75% of sales) and notes cybersecurity risk management and standard risk-factor disclosures.
FAQ
What is the current stock price of Pro-Dex Colo (PDEX)?
What is the market cap of Pro-Dex Colo (PDEX)?
